This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

QuidelOrtho Corporation
11/3/2026
Welcome to the Quidel Ortho third quarter 2026 financial results conference call and webcast. At this time, all participants lines are in a listen only mode. For those of you participating in the conference call, there will be an opportunity for your questions at the end of today's prepared remarks. Please note this conference call is being recorded. An audio replay of the conference call will be available on the company's website shortly after this call. I would now like to turn the call over to Sanjeev Sharma, Vice President of Investor Relations. Sanjeev, please go ahead.
Good afternoon, everyone, and thank you for joining us on our earnings call. With us today, we have Brian Blaser, our President and Chief Executive Officer, and Micah Young, our Chief Financial Officer. This conference call is being simultaneously webcast on the IR section of our website. To assist in the presentation, we also posted supplemental information on the investor relations page that will be referenced throughout this call. Please note that this conference call and supplemental information contain forward-looking statements, including the company's expectations, plans, financial guidance, and various strategic initiatives. We assume no obligation to update any forward-looking statement except as required by law. These statements are made as of today and are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in these statements. Please refer to our SEC filings for a description of potential risks. In addition, today's call includes discussion of certain non-GAAP financial measures. Tables reconciling these non-GAAP measures to their most directly comparable GAAP measures are available in our earnings release and supplemental information on the investor relations page of our website. Lastly, unless stated otherwise, all year-over-year revenue growth rates given on today's call are on a constant currency basis. With that, I would like to turn the call over to our president and CEO, Brian Blaser.
Thanks, Sanjeev, and good afternoon, everyone. I'd like to begin with three important takeaways from the quarter. First, the underlying performance of our business remains resilient. Labs and immunohematology, which represent 70 to 75% of our revenue, excluding China, delivered low to mid single digit organic growth. Second, our reported results continued to reflect two significant near-term headwinds. The impact of China's now finalized nationwide IOD pricing guidelines and a softer respiratory testing environment in point of care. Third, we are acting decisively and launching a new cost transformation and enterprise restructuring program designed to improve profitability and cash generation while evolving our operating model around the distinct needs of our customers and markets. These actions are intended to strengthen execution today and position Quidel Ortho for sustainable, profitable growth over the long term. Turning to our third quarter results, Total reported revenue was $619 million, down 12% from last year. Revenue increased 3%, excluding China, respiratory, and the prior year contribution from the U.S. donor screening business, which we're winding down. Labs revenue outside China grew 4%, supported by the strength and durability of our customer relationships and large global installed base. Immunohematology revenue outside China increased 3%, reflecting steady demand across key markets and our strong position in the segment. Together, these results reinforce an important point. The underlying fundamentals of our business remain healthy. We serve large and attractive diagnostic markets, hold leading positions across multiple categories, and benefit from recurring revenue streams supported by long-term customer relationships and a substantial installed base. Point of care revenue declined 27% year over year, including a 39% decline in respiratory revenue. As anticipated, respiratory demand remained below the prior year period. Given the inherent variability of respiratory trends, our outlook continues to reflect cautious assumptions for the balance of the year based on activity through the end of the third quarter. China revenue declined 45% year over year, as distributors and customers continue to reduce purchasing and inventory levels related to the nationwide IVD pricing guidelines, which were finalized in mid-August. Implementation of the guidelines is expected to begin in six provinces by the end of this year with timing determined at the provincial level. The final guidelines were generally consistent with the second draft released in June and broadly removed pricing differentiation by methodology. Provincial implementation timing remains uncertain. Based on what we know today, we expect continued destocking throughout the remainder of 2026 and increased pricing pressure in 2027 as pricing changes are implemented throughout next year. We are managing this transition with urgency and discipline. We're working closely with our China team, customers and distribution partners to adapt our commercial model as the market evolves. Our priorities are clear. Support customers, protect the installed base, align costs with expected business activity, and preserve the long-term value of our China franchise. Today, we also announced a new cost transformation and enterprise restructuring program to position Quidel Ortho for sustainable long-term profitable growth. We are improving our cost structure and reshaping the organization around our customers, their needs, and the economics of the business. Enterprise optimization and restructuring are the immediate parts of that work. The objective is not simply to reduce costs. It is to strengthen underlying performance. As part of this program, we are evolving our operating model around two focus businesses, Core Diagnostics and Point of Care Diagnostics. The point of care diagnostics business will include our Sophia, Triage, and NULEXA product lines aligned with near patient testing performed primarily in clinics, physicians offices, and emergency rooms. Core diagnostics will bring together our labs, immunohematology, and informatics portfolios serving the needs of clinical laboratories, hospitals, and blood banks. The new operating model is designed to increase customer focus, create clear accountability for business performance and better align technology development and investment priorities with the distinct needs of each business. We expect this program to deliver over 80 million in annual savings in 2027. These actions are intended not only to mitigate near-term China headwinds next year, but also to structurally improve quite all Ortho's earnings profile and cash generation. Our priorities remain consistent, expand profitability, improve free cash flow, and reduce leverage. Micah will provide additional details shortly. As we execute our cost and restructuring program, we plan to protect targeted investments in innovation and growth platforms where we see clear customer value, differentiated capability, and attractive returns. We remain committed to making these focused investments to enable the next phase of Quidel Ortho's growth. For example, within our labs business, we are expanding the vitros 450 launch to additional key international markets, empowering low volume and community based labs with our next generation analyzer designed to deliver differentiated dry slide performance with high quality and consistent results at lower costs. Neulexa, our point of care molecular platform is another example of our focused approach. Since closing the acquisition of Lex earlier this year, we have made meaningful progress building manufacturing and commercial launch capabilities. New Lexa remains in the early stages of launch, and we are balancing investment with disciplined cost management. Early customer engagement supports our view that its combination of molecular level performance, speed, and workflow simplicity addresses an important unmet need in the point of care market. Beyond the initial respiratory menu, Nulexa provides a scalable platform with meaningful menu expansion opportunities. Combined with our broad commercial reach and deep customer relationships in point-of-care diagnostics, we believe Nulexa can become an important contributor for our long-term growth strategy. As we enter respiratory season, our focus is on building placements, driving utilization, and expanding the installed base ahead of the 2027-2028 season. And with that, I'll turn the call over to Micah. Micah.
You're reading a preview of the QDEL Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing